• 1. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (CAS No. 741717-63-5): A Comprehensive Overview

Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate, identified by its CAS number 741717-63-5, is a significant compound in the realm of pharmaceutical chemistry. This compound belongs to the pyrazole class, which is renowned for its diverse biological activities and applications in medicinal chemistry. The presence of a trifluoromethyl group and a phenyl substituent enhances its pharmacological potential, making it a subject of extensive research and development.

The Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate molecule exhibits unique structural and chemical properties that contribute to its utility in various synthetic pathways. The trifluoromethyl group, in particular, is known for its ability to modulate the metabolic stability and binding affinity of drug candidates. This feature has garnered considerable attention in the design of novel therapeutic agents.

In recent years, there has been a surge in research focusing on the development of novel heterocyclic compounds with potential therapeutic applications. Pyrazole derivatives, including the Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate, have been extensively studied for their antimicrobial, anti-inflammatory, and anticancer properties. The structural versatility of pyrazole allows for the introduction of various functional groups, enabling the creation of compounds with tailored biological activities.

One of the most compelling aspects of this compound is its role in the synthesis of bioactive molecules. The carboxylate ester group in the molecule can be readily transformed into other functional moieties, such as amides or acids, through standard chemical reactions. This flexibility makes it an invaluable intermediate in organic synthesis and drug discovery.

The pharmacological profile of Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate has been explored in several preclinical studies. These investigations have highlighted its potential as a lead compound for further development into therapeutic agents. The trifluoromethyl group, in particular, has been shown to enhance the binding affinity to biological targets, thereby improving the efficacy of drug candidates.

Recent advancements in computational chemistry have also facilitated the study of this compound's interactions with biological targets. Molecular docking simulations have revealed that the trifluoromethyl and phenyl substituents play crucial roles in stabilizing the binding interface with enzymes and receptors. This information has been instrumental in guiding the design of more potent derivatives.

The synthesis of Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate involves multi-step organic reactions, typically starting from commercially available precursors. The process often requires careful optimization to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to streamline the synthesis and improve efficiency.

The growing interest in fluorinated compounds has further underscored the importance of this molecule. Fluorochemicals are widely recognized for their ability to enhance drug bioavailability and metabolic stability. The incorporation of a trifluoromethyl group into pharmaceutical candidates has become a common strategy to improve their pharmacokinetic properties.

In conclusion, Ethyl 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (CAS No. 741717-63-5) represents a promising compound with significant potential in pharmaceutical research and development. Its unique structural features and versatile synthetic applications make it a valuable tool for medicinal chemists. As research continues to uncover new biological activities and synthetic pathways, this compound is likely to play an increasingly important role in the discovery and development of novel therapeutic agents.

• 112055-34-2(Ethyl 1-phenyl-5-(trifluoromethyl)pyrazole-4-carboxylate)
• 113502-46-8(Ethyl 3-methyl-1-phenyl-1H-pyrazole-4-carboxylate)
• 142818-01-7(1-Phenyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid)
• 175137-38-9(Ethyl 2-(4-Fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate)
• 112055-35-3(Ethyl 1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate)
• 497833-15-5(3-Methyl-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic Acid)
• 112055-36-4(Ethyl 1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate)
• 112055-38-6(1H-Pyrazole-4-carboxylicacid, 1-(4-methoxyphenyl)-5-(trifluoromethyl)-, ethyl ester)
• 618070-60-3(ETHYL 1-(4-BROMOPHENYL)-5-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE)
• 98534-81-7(1-Phenyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic Acid)